Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin will discuss how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.

Topics to be covered

-Modeling chronic gastrointestinal disease with organ-on-a-chip technology
-Accelerating drug discovery and development with human primary intestinal cultures

  • 1629387686-5623a65455c0fb44
    Bill Thelin, PhD
    Chief Scientific Officer, Altis Biosystems
    Bill Thelin is the chief scientific officer at Altis Biosystems. He has more than 15 years of drug development experience, overseeing preclinical research from discovery to IND-filing. Prior to joining Altis, he researched epithelial ion channel and receptor pharmacology, mucosal disease, and targeted drug discovery. Thelin previously served as vice president of research at Parion Sciences. In his tenure at Parion, he helped build a portfolio of novel, first-in-class therapeutic programs for pulmonary and ophthalmic diseases. He received a PhD in cell biology at the University of North Carolina and was a postdoctoral fellow with Richard Boucher at the UNC Cystic Fibrosis Center.